Skip to content
2000
Volume 32, Issue 19
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

While it has been demonstrated that delivery of cytotoxic chemotherapy using nanoparticles greatly improves patient drug tolerance and reduces toxicity when compared to the standard formulation, the crucial question of whether they also increase anticancer efficacy remains. The CRLX101 is a nanoparticle composed of cyclodextrin and 20(S)-camptothecin cytotoxic chemotherapy.

Objective

In order to compare the efficacy of the CRLX101 to its corresponding traditional formulation, we carried out this systematic literature search for randomized clinical and non-randomized trials.

Methods

Multiple electronic databases, including PubMed, Scopus, Embase, Web of Science, the Cochrane Library, and clinicaltrials.gov, were used to conduct a thorough literature search. By employing a technique akin to a random-effects model, the median of the study-specific was taken into account as the pooled median estimate with a 95% confidence interval.

Results

Finally, nine clinical studies were chosen for the meta-analysis. The treatment and control groups' overall survival were examined in five and three trials, respectively. Additionally, six out of nine trials and two out of nine trials, respectively, examined the treatment and control groups for progression-free survival (PFS). Meta-analysis revealed that the treatment group had a lower median overall survival (OS) but a greater median progression-free survival than the control group.

Conclusion

Our meta-analysis shows that CRLX101 outperforms camptothecin in PFS despite its inferior OS. Unresolved pharmacology limits carrier-mediated drug therapeutic application. Carrier-mediated dosages may differ from normal formulations because they are rarely studied.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673263933231206101556
2024-02-20
2025-10-11

  • From This Site

    /content/journals/cmc/10.2174/0109298673263933231206101556
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PramanikD. Development of antibody-drug conjugates: Future perspective towards solid tumor treatment.Anticancer. Agents Med. Chem.20232366425736321237
     [Google Scholar]
  2. AlmeidaA. CastroF. ResendeC. LúcioM. SchwartzS.Jr SarmentoB. Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer.J. Control. Release202234973174310.1016/j.jconrel.2022.07.02935905784
     [Google Scholar]
  3. AlshammariM.K. AlshehriM.M. AlshehriA.M. AlshlaliO.M. MahzariA.M. AlmalkiH.H. KulaybiO.Y. AlghazwniM.K. KamalM. ImranM. Camptothecin loaded nano-delivery systems in the cancer therapeutic domains: A critical examination of the literature.J. Drug Deliv. Sci. Technol.202279104034
     [Google Scholar]
  4. BukowskiK. KciukM. KontekR. Mechanisms of multidrug resistance in cancer chemotherapy.Int. J. Mol. Sci.2020219323310.3390/ijms2109323332370233
     [Google Scholar]
  5. LiF. JiangT. LiQ. LingX. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Am. J. Cancer Res.20177122350239429312794
     [Google Scholar]
  6. GaurS. WangY. KretznerL. ChenL. YenT. WuX. YuanY.C. DavisM. YenY. Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.Nanomedicine20141071477148610.1016/j.nano.2014.04.00324768630
     [Google Scholar]
  7. YuanX. LiuL. WangW. GaoY. ZhangD. JiaT. ZengH. PanG. YuanY. Development of (G3-C12)-mediated camptothecin polymeric prodrug targeting to Galectin-3 receptor against androgen-independent prostate cancer.Int. J. Pharm.202058011912310.1016/j.ijpharm.2020.11912332035258
     [Google Scholar]
  8. YanW. YingzeW. XiaoliL. WeiZ. XinheX. ZhongxiaoH. XingjieL. Camptothecin-based nanodrug delivery systems.Cancer Biol. Med.201714436337010.20892/j.issn.2095‑3941.2017.009929372102
     [Google Scholar]
  9. MartinoE. Della VolpeS. TerribileE. BenettiE. SakajM. CentamoreA. SalaA. CollinaS. The long story of camptothecin: From traditional medicine to drugs.Bioorg. Med. Chem. Lett.201727470170710.1016/j.bmcl.2016.12.08528073672
     [Google Scholar]
  10. SchmidtK.T. PeerC.J. HuitemaA.D.R. WilliamsM.D. WroblewskiS. SchellensJ.H.M. MadanR.A. FiggW.D. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.J. Pharm. Biomed. Anal.202018111307310.1016/j.jpba.2019.11307331927166
     [Google Scholar]
  11. YoungC. SchluepT. HwangJ. EliasofS. CRLX101 (formerly IT-101) – A novel nanopharmaceutical of camptothecin in clinical development.Curr. Bioact. Compd.20117181410.2174/15734071179516386622081768
     [Google Scholar]
  12. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. PRISMA Group Preferred reporting items for systematic reviews and meta- analyses: The PRISMA statement.Ann. Intern. Med.20091514264269, W6410.7326/0003‑4819‑151‑4‑200908180‑0013519622511
     [Google Scholar]
  13. ParmarM.K.B. TorriV. StewartL. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.Stat. Med.199817242815283410.1002/(SICI)1097‑0258(19981230)17:24<2815::AID‑SIM110>3.0.CO;2‑89921604
     [Google Scholar]
  14. FurlanA.D. PennickV. BombardierC. van TulderM. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group.Spine200934181929194110.1097/BRS.0b013e3181b1c99f19680101
     [Google Scholar]
  15. McGrathS. ZhaoX. QinZ.Z. SteeleR. BenedettiA. One-sample aggregate data meta-analysis of medians.Stat. Med.201938696998410.1002/sim.801330460713
     [Google Scholar]
  16. ConoverW.J. Practical Nonparametric StatisticsJohn Wiley & sons1999350
     [Google Scholar]
  17. SanoffH.K. MoonD.H. MooreD.T. BolesJ. BuiC. BlackstockW. O’NeilB.H. SubramaniamS. McReeA.J. CarlsonC. LeeM.S. TepperJ.E. WangA.Z. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.Nanomedicine20191818919510.1016/j.nano.2019.02.02130858085
     [Google Scholar]
  18. SalgiaR. Neoadjuvant chemoradiotherapy with CRLX-101 and capecitabine for rectal cancer.Available from: https://clinicaltrials.gov/ct2/show/results/NCT02010567?te rm=NCT02010567&draw=2&rank=1&view=results
    [Google Scholar]
  19. VossM.H. HussainA. VogelzangN. LeeJ.L. KeamB. RhaS.Y. VaishampayanU. HarrisW.B. RicheyS. RandallJ.M. ShafferD. CohnA. CrowellT. LiJ. SenderowiczA. StoneE. FiglinR. MotzerR.J. HaasN.B. HutsonT. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.Ann. Oncol.201728112754276010.1093/annonc/mdx49328950297
     [Google Scholar]
  20. KeefeS.M. Hoffman-CensitsJ. CohenR.B. MamtaniR. HeitjanD. EliasofS. NixonA. TurnbullB. GarmeyE.G. GunnarssonO. WalikiM. CiconteJ. JayaramanL. SenderowiczA. TellezA.B. HennessyM. PiscitelliA. VaughnD. SmithA. HaasN.B. Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I–IIa clinical trial.Ann. Oncol.20162781579158510.1093/annonc/mdw18827457310
     [Google Scholar]
  21. DuskaL.R. KrasnerC.N. O’MalleyD.M. HaysJ.L. ModesittS.C. MathewsC.A. MooreK.N. ThakerP.H. MillerA. PurdyC. ZamboniW.C. LucasA.T. SupkoJ.G. SchilderR.J. A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.Gynecol. Oncol.2021160368869510.1016/j.ygyno.2020.12.02533390325
     [Google Scholar]
  22. WeissG.J. ChaoJ. NeidhartJ.D. RamanathanR.K. BassettD. NeidhartJ.A. ChoiC.H.J. ChowW. ChungV. FormanS.J. GarmeyE. HwangJ. KalinoskiD.L. KoczywasM. LongmateJ. MeltonR.J. MorganR. OliverJ. PeterkinJ.J. RyanJ.L. SchluepT. SynoldT.W. TwardowskiP. DavisM.E. YenY. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.Invest. New Drugs2013314986100010.1007/s10637‑012‑9921‑823397498
     [Google Scholar]
  23. GarmeyE. A phase 2 study of CRLX101(NLG207) in patients with advanced non-small cell lung cancer.Available from: https://clinicaltrials.gov/ct2/show/results/NCT01380769?term=NCT01380769&draw=2&rank=1
  24. SchmidtK.T. KarzaiF. BilusicM. CordesL.M. ChauC.H. PeerC.J. WroblewskiS. HuitemaA.D.R. SchellensJ.H.M. GulleyJ.L. DahutW.L. FiggW.D. MadanR.A. A single-arm phase II study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide.Oncologist2022279718e69410.1093/oncolo/oyac10035640474
     [Google Scholar]
  25. ChaoJ. LinJ. FrankelP. ClarkA.J. WileyD.T. GarmeyE. FakihM. LimD. ChungV. LuevanosE. EliasofS. DavisM.E. YenY. Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.J. Gastrointest. Oncol.20178696296910.21037/jgo.2017.08.1029299355
     [Google Scholar]
  26. SalgiaR. Topotecan hydrochloride or cyclodextrin-based polymer-camptothecin CRLX101 in treating patients with recurrent small cell lung cancer.Available from: https://clinicaltrials.gov/ct2/show/study/NCT01803269
  27. MichielsS. SaadE.D. BuyseM. Progression-free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumors.Drugs201777771371910.1007/s40265‑017‑0728‑y28337673
     [Google Scholar]
  28. BelinL. TanA. De RyckeY. DechartresA. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review.Br. J. Cancer2020122111707171410.1038/s41416‑020‑0805‑y32214230
     [Google Scholar]
  29. SchmidtK.T. HuitemaA.D.R. DorloT.P.C. PeerC.J. CordesL.M. SciutoL. WroblewskiS. PommierY. MadanR.A. ThomasA. FiggW.D. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.Cancer Chemother. Pharmacol.202086447548610.1007/s00280‑020‑04134‑932897402
     [Google Scholar]
  30. ChirilaC. OdomD. DevercelliG. KhanS. SherifB.N. KayeJ.A. MolnárI. SherrillB. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.Int. J. Colorectal Dis.201227562363410.1007/s00384‑011‑1349‑722076612
     [Google Scholar]
  31. JinB. KennedyX. HylandsS.A. PędziwiatrM. KuriyamaM. GomaaA. LeeY. KatsuraM. TadaM. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: A systematic review and quantitative analysis.JAMA Intern. Med.20181781215861596
     [Google Scholar]
  32. ChenE.Y. RaghunathanV. PrasadV. An overview of cancer drugs approved by the us food and drug administration based on the surrogate end point of response rate.JAMA Intern. Med.2019179791592110.1001/jamainternmed.2019.058331135822
     [Google Scholar]
  33. HiraiT. NemotoA. ItoY. MatsuuraM. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.Breast Cancer Res. Treat.2020181118919810.1007/s10549‑020‑05615‑432246379
     [Google Scholar]
  34. SherrillB. KayeJ.A. SandinR. CappelleriJ.C. ChenC. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.OncoTargets Ther.2012528729610.2147/OTT.S3668323109809
     [Google Scholar]
  35. PetersenG.H. AlzghariS.K. CheeW. SankariS.S. La-BeckN.M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.J. Control. Release201623225526410.1016/j.jconrel.2016.04.02827108612
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673263933231206101556
Loading
Clinical Outcomes and Effectiveness of CRLX101 for Solid Tumors: A Systematic Review and Meta-analysis
Curr. Med. Chem. 32, 3850 (2025); https://doi.org/10.2174/0109298673263933231206101556
/content/journals/cmc/10.2174/0109298673263933231206101556
/content/journals/cmc/10.2174/0109298673263933231206101556
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): cancer; CRLX101; EP0057; IT-101; neoplasm; NLG207; solid tumor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test